ArTara Therapeutics, Inc. (TARA)
Stock Price:
$26.20 USD
1.15 (4.59%)
Updated Aug 4, 2020 3:22 PM EDT - Market open
Key Info
| Market Cap |
153.49M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-20.35M |
| Shares Out |
5.84M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 4, 2020 |
| Last Price |
$26.20 |
| Previous Close |
$25.05 |
| Change ($) |
1.15 |
| Change (%) |
4.59% |
| Day's Open |
25.34 |
| Day's Range |
24.73 - 26.37 |
| Day's Volume |
8,317 |
| 52-Week Range |
19.22 - 67.08 |
More Stats
| Market Cap |
153.49M |
| Enterprise Value |
124.80M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
5.84M |
| Float |
803,009 |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
-3.03 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
46,341 |
| Short Ratio |
1.32 |
| Short % of Float |
2.40% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
2.33 |
| Revenue |
n/a |
| Operating Income |
-20.66M |
| Net Income |
-20.35M |
| Free Cash Flow |
-17.72M |
| Net Cash |
28.69M |
| Net Cash / Share |
4.90 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
8,749.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$47.50*
(81.30% upside)
Low
45.0
Current: $26.20
High
50.0
Target: 47.50
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | - | - | - | - | - | 2.95 | - | - |
| Gross Profit | - | - | - | - | - | 2.95 | - | - |
| Operating Income | -15.25 | -21.37 | -30.36 | -28.71 | -20.87 | -7.58 | -7.12 | -8.00 |
| Net Income | -14.99 | -20.73 | -29.96 | -28.53 | -21.38 | -3.34 | -7.91 | -7.97 |
| Shares Outstanding | 0.50 | 0.45 | 0.43 | 0.41 | 0.41 | 0.08 | 0.01 | 0.01 |
| Earnings Per Share | -30.15 | -45.80 | -85.20 | -68.80 | -52.00 | -126.40 | -2,386.40 | -2,446.40 |
| Operating Cash Flow | -15.65 | -23.23 | -22.35 | -23.69 | -17.57 | -9.99 | -6.66 | -8.23 |
| Capital Expenditures | -0.02 | -0.12 | -0.04 | -0.27 | -0.20 | -0.05 | 0.06 | -0.03 |
| Free Cash Flow | -15.66 | -23.35 | -22.39 | -23.96 | -17.76 | -10.04 | -6.60 | -8.27 |
| Cash & Equivalents | 0.56 | 21.89 | 42.16 | 41.32 | 65.26 | 83.60 | 5.15 | 7.47 |
| Total Debt | - | - | - | - | - | - | 3.73 | - |
| Net Cash / Debt | 0.56 | 21.89 | 42.16 | 41.32 | 65.26 | 83.60 | 1.43 | 7.47 |
| Assets | 1.22 | 23.52 | 43.98 | 43.52 | 67.54 | 84.80 | 5.66 | 7.78 |
| Liabilities | 3.35 | 3.08 | 9.24 | 5.08 | 4.13 | 2.34 | 9.77 | 4.15 |
| Book Value | -2.13 | 20.44 | 34.74 | 38.44 | 63.41 | 82.46 | -101 | -86.66 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
ArTara Therapeutics, Inc. |
| Country |
United States |
| CEO |
Jesse Shefferman |
Stock Information
| Ticker Symbol |
TARA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: TARA |
Description
Protara Therapeutics, Inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is based in New York, New York.